Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Validated Outcome Measures and Clinical Trial Progress in Cutaneous Lupus
Description
The speaker reviewed progress in cutaneous lupus erythematosus (CLE) outcome measurement and clinical trial development, highlighting work from a long-running CLE registry at UT Southwestern that has followed hundreds of patients across more than a thousand visits. They explained that older trials relied on subjective assessments and lacked patient-reported measures, which hindered drug development and FDA alignment. The talk focused on validated tools now used in CLE trials: the CLASI/CLAS-C, which separately measures disease activity and damage, and the cutaneous lupus activity investigator global assessment (IGA), a five-point severity scale recently validated for trials. The speaker described a multi-stakeholder working group with academia, industry, patient advocates, and the FDA that helped resolve concerns about CLASI use and established it as a viable instrument for treatment-response assessment, while noting remaining questions such as clinically meaningful improvement thresholds, minimum entry scores, and defining low disease activity. They also discussed patient-reported quality-of-life measures, especially a CLE-specific Skindex-based instrument and CLE-QOL, developed and validated with added questions about alopecia, photosensitivity, and dispigmentation. Overall, the speaker emphasized that CLE research is entering a more mature phase with standardized, validated outcome measures for clinical trials.
View moreConclusions
- CLE trials historically suffered from subjective, unvalidated severity measures and a lack of patient-reported outcomes, which hindered drug development and delayed new treatments.
- CLASI emerged as a validated and more standardized clinician-reported measure that separates disease activity from permanent damage in cutaneous lupus.
- Consensus-building efforts among academia, industry, patients, and the FDA have now supported CLASI as a reasonable instrument for assessing treatment response in CLE trials.
- Important unanswered questions remain for CLASI, including what threshold defines clinically meaningful improvement, what minimum score should qualify patients for trials, and what score range represents low disease activity.
- The CLA-IGA provides a simplified, validated 5-point clinician global assessment that is now being used in clinical trials as another way to measure CLE activity.
- Disease-specific quality-of-life assessment is essential in CLE, and CLEQoL was developed to capture patient concerns such as photosensitivity, alopecia, dyspigmentation, symptoms, emotions, and functioning.
- Overall, the field appears to be moving toward a more robust and accepted set of validated outcome measures that should improve the quality and interpretability of future CLE clinical trials.
- Albrecht J, Werth VP, et al. J Invest Dermatol. 2005;125:889-894.
- Lu G, Chong BF, et al. Nat Rev Rheumatol. 2026;22:272-278.
- Guo L, Werth VP, Merola J et al. Lupus Sci Med. 2021;8:e000529.
- Merola JF et al. J Invest Dermatol. 2025;145:2085-2088.